Information de reference pour ce titreAccession Number: | 00134415-200407000-00017.
|
Author: | Shankar, Meena a; Lee, Christine A. b; Sabin, Caroline A. c; Economides, Demetrios L. a; Kadir, Rezan A. a
|
Institution: | (a)Department of Obstetrics and Gynaecology, Royal Free Hospital, London, UK (b)Haemophilia Centre and Haemostasis Unit, Royal Free Hospital, London, UK (c)Department of Primary Care and Population Sciences, Royal Free and UC Medical School, London, UK
|
Title: | |
Source: | BJOG: An International Journal of Obstetrics & Gynaecology. 111(7):734-740, July 2004.
|
Abstract: | Objective: To determine the prevalence of von Willebrand disease in women presenting with menorrhagia.
Design: Systematic review of studies evaluating the prevalence of von Willebrand disease in women with menorrhagia.
Setting: Hospital outpatient clinics (mainly gynaecological) and population surveys.
Population: Women presenting with menorrhagia.
Methods: Relevant studies were extracted from MEDLINE search, bibliographies of identified articles and published proceedings of meetings and conferences.
Main outcome measures: Number of women with von Willebrand disease.
Results: Eleven studies were included, totalling 988 women with menorrhagia. One hundred and thirty-one women were diagnosed to have von Willebrand disease with prevalences in individual studies ranging from 5% to 24%. The overall prevalence was 13% (95% CI 11-15.6%). The prevalence was higher in the European studies-18% (95% CI 15-23%) compared with that in North American studies-10% (95% CI 7.5-13%). This difference (P = 0.007) is likely to be the result of differences in the studies, which include method of recruitment of study population, method of assessing menstrual blood loss ethnic composition of study population, criteria for diagnosis and use of race- and ABO blood group-specific values for von Willebrand factor.
Conclusions: The prevalence of von Willebrand disease is increased in women with menorrhagia and is the underlying cause in a small but significant group of women with menorrhagia across the world. Testing for this disorder should be considered when investigating women with menorrhagia, especially those of Caucasian origin, those with no obvious pelvic pathology or with additional bleeding symptoms.
Copyright (C) 2004 Blackwell Publishing Ltd.
|
References: | 1. Royal College of General Practitioners, Office of Population Censuses and Surveys, Department of Health and Social Security. Morbidity statistics from general practice. Third National Study 1981-1982. Series MBS No. 1. London: HMSO, 1986.
2. Bradlow J, Coulter A, Brooks P. Patterns of Referral. Oxford: Health Services Research Unit, 1992.
3. Rees M. Menorrhagia. BMJ 1987;294: 759-762.
4. Evans PC. Obstetric and gynecologic patients with von Willebrand's disease. Obstet Gynecol 1971;38: 37-43.
5. Fraser IS, McCarron G, Markham R, Resta T, Watts A. Measured menstrual blood loss in women with menorrhagia associated with pelvic disease or coagulation disorder. Obstet Gynecol 1986;68: 630-633.
6. Greer IA, Lowe GD, Walker JJ, Forbes CD. Haemorrhagic problems in obstetrics and gynaecology in patients with congenital coagulopathies. Br J Obstet Gynaecol 1991;98: 909-918.
7. Frederici AB, Manucci PM. Advances in the genetics and treatment of von Willebrand disease. Curr Opin Pediatr 2002;14: 23-33.
8. Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Variations in coagulation factors in women: effects of age, ethnicity, menstrual cycle and combined oral contraceptive. Thromb Haemost 1999;82: 1456-4561.
9. Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr 1993;123: 893-898.
10. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987;69: 454-459.
11. Edlund M, Blomback M, von Schoultz B, Andersson O. On the value of menorrhagia as a predictor of coagulation disorders. Am J Hematol 1996;53: 234-238.
12. Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998;351: 485-489.
13. Woo YL, White B, Corbally M, et al. Von Willebrand's disease: an important cause of dysfunctional bleeding. Blood Coagul Fibrinolysis 2002;13: 89-92.
14. Krause M, Aygoren-Pursun E, Ehrenforth S, Ludwig G, Vigh TH, Scharrer I. Coagulation disorders in women with menorrhagia Haemophilia 2000;6: 240-247.
15. Kouides P, Phatak P, Sham R, et al. The prevalence of subnormal von Willebrand factor levels in menorrhagia patients in Rochester NY: a final analysis. Haemophilia 2000;6: 240-247.
16. Hambleton J, Roth J, Jurnack-Dewell J, Schwartz B, Seremetis S. Prevalence of Von Willebrand disease in women with menorrhagia: a preliminary report. Haemophilia 2000;6: 240-247.
17. Goodman-Gruen D, Hollenbach K. The prevalence of von Willebrand disease in women with abnormal uterine bleeding. J Women's Health Gend-Based Med 2001;10: 677-680.
18. Dilley A, Drews C, Miller C, et al. von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet Gynecol 2001;97: 630-636.
19. Philip CS, Dilley A, Miller CH, et al. Platelet functional defects in women with unexplained menorrhagia. Thromb Haemost 2003;1: 477-484.
20. Baindur S, Shetty S, Pathare AV, Salvi V, Ghosh K, Mohanty D. Screening for von Willebrand disease in patients with menorrhagia. Haemophilia 2000;6: 240-247.
21. Saxena R, Gupta M, Gupta PK, Kashyap R, Choudhry VP, Bhargava M. Inherited bleeding disorders in Indian women with menorrhagia. Haemophilia 2003;9: 193-196.
22. El Ekiaby M, Ahmed A, Farag O, Khattab D. von Willebrand disease as a cause of menorrhagia. Haemophilia 2002;8: 512-514.
23. Hallberg L, Hogdahl AM, Nilsson L, Rybo G. Menstrual blood loss-a population study. Acta Obstet Gynecol Scand 1966;45: 320-351.
24. Haynes PJ, Hodgson H, Anderson ABM, Turnbull AC. Measurement of menstrual blood loss in patients complaining of menorrhagia. Br J Obstet Gynaecol 1977;84: 763-768.
25. Fraser IS, McCarron G, Markham R. A preliminary study of factors influencing perception of menstrual blood loss volume. Am J Obstet Gynecol 1984;149: 788-793.
26. Chimbira TH, Anderson ABM, Turnbull AC. Relation between measured menstrual blood loss and patients subjective assessment of loss, duration of bleeding, number of sanitary towels used, uterine weight and endometrial surface area. Br J Obstet Gynaecol 1980;87: 603-609.
27. Hallberg L, Nilsson L. Determination of menstrual blood loss. Scan J Clin Lab Invest 1964;16: 244-248.
28. Higham LM, O'Brien PMS, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 1990;97: 734-739.
29. Conlam MG, Folsam AR, Finch A, et al. Associations of factor VIII and von Willebrand factor with age, race, sex and risk factors for atherosclerosis. The atheroscelosis risk in communities (ARIC) study. Thromb Haemost 1993;70: 380-385.
30. Green D, Ruth KJ, Folsom AR, Liu K. Hemostatic factors in coronary artery risk development in young adults (CARDIA) study. Arterioscler Thromb 1994;14: 686-689.
31. Sukhu K, Poovalingam V, Mahomed R, Giaugrandi PL. Ethnic variation in von Willebrand factor levels can influence the diagnosis of von Willebrand disease. Clin Lab Haematol 2003;25: 247-249.
32. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987;69: 1691-1695.
33. Nitu-Whalley IC, Lee CA, Griffioen A, Jenkins PV, Pasi KJ. Type 1 von Willebrand disease-a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history. Br J Haematol 2000;108: 259-264.
34. Werner EJ, Abshire TC, Giroux DS, Tucker EL, Broxson EH. Relative value of diagnostic studies for von Willebrand disease. J Pediatr 1992;12: 34-38.
35. Rodeghiero F, Castaman G, Tosetto A. von Willebrand factor antigen is less sensitive than ristocetin cofactor for the diagnosis of type I von Willebrand disease-results based on an epidemiological investigation. Thromb Haemost 1990;64: 349-352.
36. Riddell AF, Jenkins VP, Nitu-Whalley IC, McCraw AH, Lee CA, Brown SA. Use of the collagen-binding assay for von Willebrand factor in the analysis of type 2M von Willebrand disease: a comparison with ristocetin cofactor assay. Br J Haematol 2002;116: 187-192.
37. Abildgaard CF, Suzuki Z, Harrison J, Jefcoat K, Zimmerman TS. Serial studies in von Willebrand's disease: variability versus 'variants'. Blood 1980;56: 712-716.
38. Mandalaki T, Louizou C, Dimitriadou C, Symeonidis P. Variations in factor VIII during the menstrual cycle in normal women. N Engl J Med 1980;302: 1093-1094.
39. Miller CH, Dilley AB, Drew SC, Richardson L, Evatt B. Changes in von Willebrand factor and factor VIII levels during the menstrual cycle. Thromb Haemost 2002;87: 1082-1083.
40. Onundarson PT, Gudmundsdottir BR, Arntinnsdottir AV, Kjeld M, Olafasson O. von Willebrand factor does not vary during the normal menstrual cycle. Thromb Haemost 2001;85: 183-184.
41. Blomback M, Eneroth P, Andersson O, Anvret M. On laboratory problems in diagnosing mild von Willebrand's disease. Am J Hematol: 1992;117-120.
42. Blomback M, Eneroth P, Landgren BM, Lagerstrom M, Anderson O. On the intraindividual and gender variability of haemostatic components. Thromb Haemost 1992;67: 70-75.
43. Nilsson IM. Von Willebrand's disease-fifty years old. Acta Med Scand 1977;201: 497-508.
44. Beller FK, Ebert C. Effects of oral contraceptives on blood coagulation. A review. Obstet Gynaecol Surv 1985;40: 425-426.
45. Prasad RN, Koh SC, Viegas OA, Ratnam SS. Effects on haemostasis after two year use of low dose combined oral contraceptive with gestodene or levonorgestrol. Clin Appl Thromb Hemost 1999;51: 60-70.
46. Harris GM, Stendt CL, Vollenhoven BJ, Gan TE, Tipping PG. Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives. Am J Hematol 1999;60: 175-180.
47. Sramek A, Eikenboom JC, Briet E, Vandenbroucke JP, Rosendaal FR. Usefulness of patient interview in bleeding disorders. Arch Intern Med 1995;155: 1409-1415.
48. Fressinaud E, Veyradier A, Truchand F, et al. Screening for von Willebrand disease with a new analyzer using high sheer stress: a study of five cases. Blood 1998;91: 1325-1331.
49. Rose EH, Aledort LM. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease. Ann Intern Med 1991;114: 563-568.
|
Language: | English.
|
Document Type: | GYNAECOLOGY.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 1470-0328
|
NLM Journal Code: | 100935741
|
Annotation(s) | |
|
|